65,437 trials
Nonsquamous Non-small Cell Lung Cancer
Primary: Part 1: Number of Participants With a Dose-limiting Toxicity (DLT) — 2 Participants
Multiple Sclerosis · Immune System Diseases
Primary: Number of Participants With Complete Depletion of B Cells — 15; 0; 0; 0 Participants — p=0.05
Multiple Sclerosis
Primary: Annualized Confirmed Relapse Rate (ARR) — 0.143; 0.184 relapses per patient-year
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC[0-t]) of Digoxin in Plasma — 14.6; 17.1; 48.9…
Antibiotic-associated Diarrhea
Primary: Number of Participants Experiencing Diarrhea — 3; 2; 122; 128 Participants
Hereditary Angioedema (HAE)
Primary: Number of Participants With Adverse Events — 22 Participants
Spinal Cord Injury · Autonomic Dysreflexia · Orthostatic Hypotension
Primary: Affected Therapy Sessions — 16.4; 10.9 percentage of sessions
Myeloid Malignancy
Primary: To Evaluate the Tolerabililty and the Incidence of Treatment-Emergent Adverse Events of Administration of APR 246 in Combination With Venetoclax and Azacitidine in…
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Solicited Local Adverse Events (AE) During 7 Days After Vaccination — 5; 9; 16; 19 Participants
Alcohol Use Disorder · Couples
Primary: Change in Percent Days Abstinent - Measured by Time Line Follow Back (TLFB) — 36.8; 35.9 percentage of days abstinent for alcohol
Covid19
Primary: Covid (Coronavirus Disease-19) Ordinal Scale — 2.3; 2.1 score on a scale
Gingival Inflammation
Primary: Plaque Index Score at Baseline — 2.80; 2.78 Score on a scale
Chronic Kidney Disease Associated Moderate to Severe Pruritus
Primary: Percentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 12 — 38.5; 47.7; 32.4…
Executive Function
Primary: Task Switch Test Response Times — 783.97; 788.76; 839.46; 566.46 millisecond
Gastric Cancer · Gastroesophageal Junction Cancer
Primary: Event-free Survival (EFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms — NA; 36.5 Months…